Bosutinib is a small molecule BCR-ABL and src tyrosine kinase inhibitor that is used in the treatment of chronic myelogenous leukemia with resistance or intolerance to prior therapy.
Bosutinib is an ATP competitive inhibitor with an additional blocking effect on src family kinases. This medication has also shown a report against the receptor of vascular endothelial growth factor and platelet-derived growth factor.
The inactive ingredients in the bosutinib tablet are microcrystalline cellulose, polyvinyl alcohol, magnesium stearate, povidone poloxamer, Titanium dioxide, iron oxide yellow, polyethylene glycol, iron oxide red, croscarmellose sodium.
Dosage and administration: Bosutinib is available in a tablet form of 100 mg and 500 mg strength. The 500 mg dose is recommended to be taken once orally with or without food. The doses of bosutinib depend on a person's weight, age, and stage of infection. However, the dose can be adjusted in case of hepatic impairment, hematologic, or non-hematologic toxicity.
Side Effects:
Some common side effect of bosutinib 500 mg are as follows:
- Nausea
- vomiting
- Abdominal pain
- Rash
- Anemia
- Diarrhea
- Pyrexia
- Thrombocytopenia
- Fatigue
Few common adverse reactions of bosutinib tablets are mentioned below:
- Hepatic toxicity: the monitoring of Liver enzyme for at least three months is necessary in case of bosutinib tablet
- Embryo-fetal toxicity: intake of bosutinib medication main cause fetal damage and can reduce the reproductive potential of women
- Fluid retention the patient stay should be monitored carefully and if any serious symptoms appear then the use of bosutinib should be discontinued
- Gastrointestinal toxicity: if any problems occur due to then I should be discontinued immediately
- Myelosuppression: blood count reduction is detected
Drug Interaction
- CYP3A Inhibitors and Inducers: Avoid concurrent use of bosutinib with strong or moderate CYP3A inhibitors and inducers.
- Proton Pump Inhibitors: in some cases, the proton pump inhibitor decreases the concentration of bosutinib tablets.
Storage and handling: Bosutinib tablets should be stored at 20°C to 25°C (68°F to 77°F). Proper handling and disposal procedures should be taken care of. Tablets should be avoided to be crushed or broken. The unused product or Tablet should be disposed of according to the anticancer drug procedure.
Read:- About Azathioprine
